AR070405A1 - COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF MACULAR DEGENERATION AND / OR LOSS OF VISUAL ACUTE - Google Patents
COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF MACULAR DEGENERATION AND / OR LOSS OF VISUAL ACUTEInfo
- Publication number
- AR070405A1 AR070405A1 ARP090100332A ARP090100332A AR070405A1 AR 070405 A1 AR070405 A1 AR 070405A1 AR P090100332 A ARP090100332 A AR P090100332A AR P090100332 A ARP090100332 A AR P090100332A AR 070405 A1 AR070405 A1 AR 070405A1
- Authority
- AR
- Argentina
- Prior art keywords
- milligrams
- usp
- composition according
- vitamin
- copper
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 208000002780 macular degeneration Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title 1
- 230000000007 visual effect Effects 0.000 title 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 4
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 4
- 239000006014 omega-3 oil Substances 0.000 abstract 4
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 abstract 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 abstract 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 abstract 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 abstract 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 3
- 235000010930 zeaxanthin Nutrition 0.000 abstract 3
- 239000001775 zeaxanthin Substances 0.000 abstract 3
- 229940043269 zeaxanthin Drugs 0.000 abstract 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- 229930003268 Vitamin C Natural products 0.000 abstract 2
- 229930003427 Vitamin E Natural products 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
- 235000012680 lutein Nutrition 0.000 abstract 2
- 229960005375 lutein Drugs 0.000 abstract 2
- 239000001656 lutein Substances 0.000 abstract 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 235000019154 vitamin C Nutrition 0.000 abstract 2
- 239000011718 vitamin C Substances 0.000 abstract 2
- 235000019165 vitamin E Nutrition 0.000 abstract 2
- 229940046009 vitamin E Drugs 0.000 abstract 2
- 239000011709 vitamin E Substances 0.000 abstract 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 abstract 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 abstract 1
- 239000005751 Copper oxide Substances 0.000 abstract 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 abstract 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 abstract 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- 150000001783 ceramides Chemical class 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 229940116318 copper carbonate Drugs 0.000 abstract 1
- 229940108925 copper gluconate Drugs 0.000 abstract 1
- 229910000431 copper oxide Inorganic materials 0.000 abstract 1
- 229910000365 copper sulfate Inorganic materials 0.000 abstract 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 abstract 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 abstract 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 235000015110 jellies Nutrition 0.000 abstract 1
- 239000008274 jelly Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 235000012424 soybean oil Nutrition 0.000 abstract 1
- 239000003549 soybean oil Substances 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 229960000306 zinc gluconate Drugs 0.000 abstract 1
- 235000011478 zinc gluconate Nutrition 0.000 abstract 1
- 239000011670 zinc gluconate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente se relaciona con una composicion de suplemento nutricional o dietético que refuerza y promueve la salud de la retina. Reivindicacion 1: Una composicion que comprende una dosis diaria de: aproximadamente de 400 a 600 miligramos de vitamina C, aproximadamente de 350 a 450 UI de vitamina E, aproximadamente de 1 a 20 miligramos de luteína; aproximadamente de 20 a 42 miligramos de zinc; aproximadamente de 1000 a 1800 miligramos de ácidos grasos omega 3, y aproximadamente de 0,8 a 1,35 miligramos de cobre. Reivindicacion 2: La composicion de acuerdo con la reivindicacion 1, la cual comprende zeaxantina, de preferencia en una cantidad de aproximadamente de 1,7 a 2,3 miligramos. Reivindicacion 3: La composicion de acuerdo con la reivindicacion 1, en donde los ácidos grasos omega 3 comprenden ácido docosahexaenoico y ácido eicosapentaenoico. Reivindicacion 9: La composicion de acuerdo con la reivindicacion 8, en donde el recubrimiento es un fosfolípido zwitterionico que incluye pero no se limita a fosfatidil-colina, fosfatidil-serina, fosfatidil-etanolamina, esfingomielina y otras ceramidas, así como varios otros fosfolípidos zwitterionicos. Reivindicacion 12: Una composicion de acuerdo con la reivindicacion 1, la cual es una tableta, cápsula o aglomerado, y comprende: 500 miligramos de vitamina C (Dihidrato de ascorbato de calcio, USP), 400 UI de vitamina E (Acetato de alfa tocoferilo, USP), 40 miligramos de gluconato de zinc, 4,7 miligramos de ?sulfato de cobre o 1,5 miligramos de oxido de cobre, 2,14 miligramos de carbonato de cobre, 8,58 miligramos de gluconato de cobre, 400 miligramos de DHA, 600 miligramos de EPA, 1200 miligramos de total de ácidos grasos Omega 3 (Triglicéridos de ácidos grasos Omega-3, Farmacopea Europea), 10 miligramos de luteína (fuente natural FloraGlo al 20 por ciento (que comprende algo de zeaxantina) o pura), 2 miligramos de zeaxantina (origen sintético), comprendiendo opcionalmente los siguientes excipientes para hacer una cubierta: gelatina 175 de bovino joven, glicerina USP 99 por ciento, hojuelas de aceite de soya (hidrogenadas) NF, aceite de soja USP, y dioxido de titanio USP. Reivindicacion 14: El uso de una composicion de acuerdo con cualquiera de las reivindicaciones anteriores, en la preparacion de un medicamento para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (AMD) y/o la retinopatía diabética (DR).This is related to a nutritional or dietary supplement composition that reinforces and promotes the health of the retina. Claim 1: A composition comprising a daily dose of: about 400 to 600 milligrams of vitamin C, about 350 to 450 IU of vitamin E, about 1 to 20 milligrams of lutein; approximately 20 to 42 milligrams of zinc; approximately 1000 to 1800 milligrams of omega 3 fatty acids, and approximately 0.8 to 1.35 milligrams of copper. Claim 2: The composition according to claim 1, which comprises zeaxanthin, preferably in an amount of about 1.7 to 2.3 milligrams. Claim 3: The composition according to claim 1, wherein the omega 3 fatty acids comprise docosahexaenoic acid and eicosapentaenoic acid. Claim 9: The composition according to claim 8, wherein the coating is a zwitterionic phospholipid that includes but is not limited to phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, sphingomyelin and other ceramides, as well as several other zwitterionic phospholipids . Claim 12: A composition according to claim 1, which is a tablet, capsule or agglomerate, and comprises: 500 milligrams of vitamin C (Calcium ascorbate dihydrate, USP), 400 IU of vitamin E (Alpha tocopheryl acetate , USP), 40 milligrams of zinc gluconate, 4.7 milligrams of? Copper sulfate or 1.5 milligrams of copper oxide, 2.14 milligrams of copper carbonate, 8.58 milligrams of copper gluconate, 400 milligrams of DHA, 600 milligrams of EPA, 1200 milligrams of total Omega 3 fatty acids (Triglycerides of Omega-3 fatty acids, European Pharmacopoeia), 10 milligrams of lutein (20 percent FloraGlo natural source (comprising some zeaxanthin) or pure), 2 milligrams of zeaxanthin (synthetic origin), optionally comprising the following excipients to make a cover: 175 young bovine jelly, 99 percent USP glycerin, NF soybean (hydrogenated) flakes, USP soybean oil, and USP titanium dioxide. Claim 14: The use of a composition according to any of the preceding claims, in the preparation of a medicament for the treatment and / or prevention of age-related macular degeneration (AMD) and / or diabetic retinopathy (DR) .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08151045 | 2008-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070405A1 true AR070405A1 (en) | 2010-04-07 |
Family
ID=39708779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100332A AR070405A1 (en) | 2008-02-04 | 2009-02-02 | COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF MACULAR DEGENERATION AND / OR LOSS OF VISUAL ACUTE |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR070405A1 (en) |
| CL (1) | CL2009000230A1 (en) |
| PE (1) | PE20091462A1 (en) |
| TW (1) | TW201000027A (en) |
| WO (1) | WO2009098186A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1393710B1 (en) * | 2009-04-29 | 2012-05-08 | Graal Srl | OROBUCCAL COMPOSITIONS CONTAINING A MIXTURE OF LUTEIN AND ZEAXANTHIN. |
| WO2013037794A1 (en) * | 2011-09-12 | 2013-03-21 | Georgiou Tassos | Use of omega fatty acids for treating disease |
| CN103211216A (en) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | Health food with function of improving memory in aided manner and preparation method thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002320251A1 (en) * | 2001-07-05 | 2003-01-21 | Vital Basics, Inc. | Compositions for improving mental performance |
| US6649195B1 (en) * | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| US7887847B2 (en) * | 2004-05-08 | 2011-02-15 | Paul Jr Edward L | Nutritional supplement for treatment of ocular diseases |
| FR2883182B1 (en) * | 2005-03-16 | 2008-02-15 | Novartis Ag | VITAMIN COMPOSITION USEFUL IN THE TREATMENT OF OCULAR DISEASES |
| DE202005012984U1 (en) * | 2005-08-17 | 2005-11-24 | W & B Pharmamarken Gmbh | Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon |
| US7829126B2 (en) * | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
| CN101330840A (en) * | 2005-12-20 | 2008-12-24 | 爱尔康研究有限公司 | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
| DE202006014588U1 (en) * | 2006-09-20 | 2006-12-14 | Orthomol Pharmazeutische Vertriebs Gmbh | Carotenoid containing product, preferably a balanced diet supplement, useful for age-related eye diseases, comprises vitamins, carotenoids, flavonoids, sulfur containing amino acids, zinc, selenium, chrome, taurine and omega-3-fatty acid |
-
2009
- 2009-02-02 AR ARP090100332A patent/AR070405A1/en unknown
- 2009-02-02 PE PE2009000147A patent/PE20091462A1/en not_active Application Discontinuation
- 2009-02-02 WO PCT/EP2009/051163 patent/WO2009098186A1/en active Application Filing
- 2009-02-03 TW TW098103403A patent/TW201000027A/en unknown
- 2009-02-03 CL CL2009000230A patent/CL2009000230A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201000027A (en) | 2010-01-01 |
| PE20091462A1 (en) | 2009-10-23 |
| WO2009098186A1 (en) | 2009-08-13 |
| CL2009000230A1 (en) | 2009-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081580A1 (en) | SUPPLEMENTARY NUTRITIONAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES | |
| CA2738357C (en) | Methods and compositions to promote ocular health | |
| RU2009126740A (en) | NUTRITION SUPPLEMENT COMPOSITION FOR THE TREATMENT OF EYE DISEASES | |
| NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
| WO2005110375A8 (en) | Nutritional supplement for treatment of ocular diseases | |
| ES2606392T3 (en) | Compositions comprising omega-3 and vitamin D fatty acids for acne vulgaris and / or eczema, and procedures and uses thereof | |
| EP3738586A1 (en) | Enteric soft capsules comprising polyunsaturated fatty acids | |
| JPWO2005061684A1 (en) | Oil composition | |
| BR112014005546A2 (en) | omega fatty acids for disease treatment | |
| JPWO2012067224A1 (en) | Treatment or prevention agent for corneal epithelial disorder and / or conjunctival epithelial disorder | |
| JP2008533075A (en) | Vitamin mixture | |
| AR070405A1 (en) | COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF MACULAR DEGENERATION AND / OR LOSS OF VISUAL ACUTE | |
| RS52735B (en) | Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases | |
| CA2681514C (en) | Use of a masked or coated copper salt for the treatment of macular degeneration | |
| Trinidad et al. | Importance of the Nutrition with Antioxidants in the Treatment of Cancer and Others Damages | |
| WO2019004969A3 (en) | Use of a vegetal formulation containing pomegranate seed oil as an assistive agent in reduction of blood lipids known as triglyceride | |
| EP4090174A1 (en) | A nutraceutical formulation | |
| PL239957B1 (en) | Oil-in-water emulsion for use in eye drops as a carrier for oil-soluble ophthalmic drug substances | |
| JP2017536367A5 (en) | ||
| MX2017001880A (en) | Nutraceutical formulation made of pilocarpus microphyllus, lactoferrin and fish oil for oral administration in human beings. | |
| EP1974733A1 (en) | Use of a masked or coated copper salt for the treatment of macular degeneration | |
| WO2017069631A1 (en) | Method for improving equilibrioception in healthy individuals and nutritional composition | |
| Gilca et al. | Current and Relevant Publications on Vitamins, Carotenoids and Other Health Ingredients Update June 2008 | |
| Crawford | Another Supplement for CAD Prevention Fails | |
| MX2016010439A (en) | Formulation for the oral administration of quercetin in human beings. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |